Search
for
Sort by
Research 121–150 of 787
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- IL-15 Prolongs Anagen, Stimulates Proliferation, and Suppresses Apoptosis in the Hair Matrix of Human Scalp Hair Follicles
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
- The Role of Janus Kinase Inhibitors in Dermatology
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Ritlecitinib: First Approval
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Tofacitinib for the treatment of lichen planopilaris: A case series
- The role of lymphocytes in the development and treatment of alopecia areata
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- A Concise Review on Novel Drugs Applied in Treatment of Alopecia